Scarica l'app Stockscreener
379.27
0.60%
2.27
Pre-mercato:
376.56
-2.71
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$377.00
Aprire:
$380
Volume 24 ore:
2.02M
Relative Volume:
0.72
Capitalizzazione di mercato:
$204.45B
Reddito:
$36.74B
Utile/perdita netta:
$7.71B
Rapporto P/E:
26.65
EPS:
14.2333
Flusso di cassa netto:
$8.10B
1 W Prestazione:
-1.32%
1M Prestazione:
+3.57%
6M Prestazione:
+35.41%
1 anno Prestazione:
+21.49%
Intervallo 1D:
$370.82
$380.09
Intervallo di 1 settimana:
$370.82
$391.29
Portata 52W:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, NVS, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
379.27 | 203.23B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
1,003.57 | 899.90B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
245.30 | 594.64B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
236.19 | 413.50B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
165.15 | 313.28B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.53 | 312.88B | 58.80B | 10.24B | 8.98B | 3.2788 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen: Wait For A Better Entry Point (Rating Downgrade) (NASDAQ:AMGN) - Seeking Alpha
Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market - GlobeNewswire Inc.
CI Investments Inc. Has $6.34 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen (AMGN) Pricing Reflect Its Recent 24% One Year Share Price Return - Yahoo! Finance Canada
Amgen (AMGN) Maintains Quarterly Dividend of $2.52 Per Share - GuruFocus
Amgen Keeps Quarterly Dividend at $2.52 a Share, Payable June 5 to Holders of Record May 15 - marketscreener.com
Amgen announces 2026 second quarter dividend - marketscreener.com
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND - PR Newswire
Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial - TipRanks
Dimensional Fund Advisors Boosts Amgen Holdings - National Today
Smith Chas P & Associates PA Cpas Sells 47,455 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Victory Capital Management Inc. - MarketBeat
Mcdonald Partners LLC Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
Dimensional Fund Advisors LP Raises Holdings in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After Its Strong Multi Year Share Price Run? - simplywall.st
AMGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amgen Inc. (AMGN) is Drawing Interest from Investors: Key Information You Need to Know - Bitget
Amgen EVP Sold $20.77M In Company Stock - Benzinga
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Amgen stock forecast for 2030: $6B patent exposure challenges $500 level - Traders Union
Fisher Asset Management LLC Acquires 375,463 Shares of Amgen Inc. $AMGN - MarketBeat
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook - Stocktwits
Amgen (NASDAQ:AMGN) Sets New 1-Year HighShould You Buy? - MarketBeat
Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally - Kalkine Media
Amgen Touts Broad Portfolio Momentum, MariTide Milestones and Repatha Access Push at TD Cowen Conf - Yahoo Finance
Amgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S Revenue Breakdown – NEO:AMGN - TradingView
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot - BioSpace
Amgen (AMGN) EVP Esteban Santos exercises options and sells 54,792 shares - Stock Titan
Amgen at TD Cowen Conference: Strategic Growth and Challenges - Investing.com India
Amgen Is Up 35% in the Last 6 Months. Here’s Where the Stock Could Go in 2026 - TIKR.com
Amgen’s Phase 3 Gout Trial Pits Subcutaneous Pegloticase Against IV Dosing - TipRanks
Amgen Inc. (AMGN) Stock Report: Evaluating the 106% Return on Equity and Market Prospects - DirectorsTalk Interviews
Laurel Wealth Advisors LLC Cuts Position in Amgen Inc. $AMGN - MarketBeat
Bahl & Gaynor Inc. Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
6,843 Shares in Amgen Inc. $AMGN Purchased by 111 Capital - MarketBeat
Amgen Deployed a Record $7.2 Billion in R&D: Here’s What Investors Should Expect - TIKR.com
How Amgen’s $4 Billion Long-Dated Bond Issuance At Amgen (AMGN) Has Changed Its Investment Story - Yahoo Finance
Amgen Recasts Growth Story With Product Momentum And Long Dated Funding - simplywall.st
Amgen Inc. (AMGN): A Bull Case Theory - Insider Monkey
Andra AP fonden Boosts Stake in Amgen - National Today
Harvest Portfolios Group Inc. Boosts Holdings in Amgen Inc. $AMGN - MarketBeat
Argent Trust Co Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Andra AP fonden Raises Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Boosted by Allianz SE - MarketBeat
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Insider plans sale of 54,792 AMGN shares (NASDAQ: AMGN) - Stock Titan
Amgen Advances Maridebart Cafraglutide Toward Mid-Stage Obesity and Liver Fat Trial - TipRanks
Amgen Fine-Tunes Evolocumab: New Bioavailability Study Signals Long-Term Cholesterol Franchise Focus - TipRanks
Amgen Nears a Nivolumab Biosimilar Milestone in Melanoma: What Investors Should Watch - TipRanks
Amgen Inc. $AMGN Shares Purchased by Sumitomo Mitsui Financial Group Inc. - MarketBeat
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.26%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):